Document is current
Any future updates will be listed below
-
Authors
Mathew, Roy O. https://orcid.org/0000-0002-5582-3165
Khan, Sadiya S. https://orcid.org/0000-0003-0643-1859
Tuttle, Katherine R. https://orcid.org/0000-0002-2235-0103
Ho, Jennifer E. https://orcid.org/0000-0002-7987-4768
Abramov, Dmitry
Bangalore, Sripal
Sidhu, Mandeep S.
Ndumele, Chiadi E.
Powell-Wiley, Tiffany M. https://orcid.org/0000-0001-9488-4131
Neeland, Ian J.
Coresh, Josef https://orcid.org/0000-0002-4598-0669
Elkind, Mitchell S. V. https://orcid.org/0000-0003-2562-1156
Rangaswami, Janani
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 21 May 2025
First Online: 4 July 2025
Competing interests
: R.O.M., S.S.K., M.S.S., C.N. and T.M.P.-W. declare no competing interests. K.R.T. is supported by NIH research grants and CDC projects. She has also received an investigator-initiated grant support from Travere Therapeutics Inc., Bayer and the Doris Duke Charitable Foundation. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Travere Therapeutics Inc. and Pfizer and speaker fees from Novo Nordisk. J.E.H. is supported by NIH research grants (see above). D.A. has received speaker fees from Bayer and AstraZeneca. S.B. is a consultant or on the advisory board of Abbott Vascular, Boston Scientific, Medtronic, Amgen, Pfizer, Inari, Truvic and Shockwave. J.C. is supported by NIH grants co-funded by the Doris Duke Foundation (see above). I.J.N. has received speaker fees from Boehringer Ingelheim/Lilly Alliance and Bayer, and is on the consulting or advisory board of Novo Nordisk, Lilly and Boehringer Ingelheim. M.S.V. is an employee of the AHA. J.R. has been a consultant for Boehringer Ingelheim, Bayer and is on the Medical Advisory Board for Procyrion.
